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Background
Severe/Non-controlled asthma (SNCA) is a crucial chal-
lenge for physicians and a socio-economic burden for
National Health Services (NHS). In Italy more than 50% of
costs for asthma (1-2% of total NHS expenditure) are due
to SNCA and moreover, within the European Community
Respiratory Health Survey, Italy was the country with the
lowest % of ICS daily use (29%) and with the highest % of
subjects with uncontrolled asthma despite treatment (67%
vs an overall European mean of 47%). Despite few data
from very selected centers, in our country a precise esti-
mate of the epidemiological figures and the disease related
costs for SNCA is not available. Thus, we aimed at insti-
tuting of an on-line Italian register for SNCA (Registro
Italiano Asma Grave e Non Controllata) published on the
website of the Italian Health Agency (Istituto Superiore di
Sanità -ISS) and financed by the Italian Drug Agency
(Agenzia Italiana per il Farmaco – AIFA). Objectives To
assess in general population and in clinical settings the
effectiveness of therapeutic strategies for SNCA, defined in
accordance with GINA guidelines. Secondary objectives
are: obtain clinical indicators of diagnostic and therapeutic
appropriateness for SNCA, evaluate direct and indirect
costs of this disease, obtain continuous monitoring of
SNCA patients, some epidemiological figures and finally
disseminate the use of the register among Italian clinical
centers.
Methods
The register is composed of 9 different sections and a
follow-up section accessible, at present, only to the 8
centers participating in the AGAVE (severe asthma: epi-
demiological and clinical cohorts follow up; therapeutic
appropriateness and outcome assessment) project,
financed by AIFA. These centers will use the register to
enter clinical data from their SNCA patients. All patients
with a diagnosis of severe asthma since at least one year
and all uncontrolled asthma despite regular treatment
according to GINA step 3 or 4 are eligible. Patients will
be selected from prospective and retrospective longitudi-
nal studies of pre-existing cohorts of different age groups
and different geographical areas. Follow-up will be per-
formed every 6 months for 24 months. The estimated
number of recruited patients from the clinical setting is
375, while 500 patients are expected from the epidemio-
logical setting.
Conclusions
Our goal is to collect more data on SNCA patients and
disseminate the on-line register for use by National
Health Service physicians.
Author details
1Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica, Italy.
2Università degli Studi di Palermo, Malattie dell’Apparato Respiratorio, Italy.
3Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Dipart Malattie
Respiratorie e Immunoallergiche, Italy. 4Università di Verona, Unità di
Epidemiologica e Statistica Medica, Italy. 5Regione Lazio, Dipartimento di
Epidemiologia, Italy. 6Università di Pisa, Dipartimento Cardio Toracico e
Vascolare, Italy. 7Università di Genova, Dip Medicina, Malattie Allergiche
e Respiratorie, Italy. 8Università di Perugia, Dipartimento di Medicina Clinica e
Sperimentale, Italy.
Published: 3 May 2013
doi:10.1186/2045-7022-3-S1-P16
Cite this article as: Bresciani et al.: On-line Italian register for severe/
non-controlled asthma. Clinical and Translational Allergy 2013 3(Suppl 1):
P16.
1Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica, Italy
Full list of author information is available at the end of the article
Bresciani et al. Clinical and Translational Allergy 2013, 3(Suppl 1):P16
http://www.ctajournal.com/content/3/S1/P16
© 2013 Bresciani et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
